JASTLabs is bringing a patent-pending breakthrough to millions of women worldwide, and to accredited investors at $2 a share.
Private investment involves risk, including loss of capital.
Estrogen-based hormone therapy is the standard of care for menopause symptoms. Vaginal atrophy, diminished libido, hot flashes, sleep disruption. It works. It also carries a risk profile that has shadowed the category since the day it launched.
Estrogen therapy is associated with elevated risk of breast cancer, stroke, blood clots, cardiovascular disease, endometrial cancer, and gallbladder disease. The Women's Health Initiative made those risks public in 2002, and prescribing collapsed almost overnight. A generation of women either quit, never started, or were told by their doctors to avoid it.
For some women, estrogen is off the table entirely. Breast cancer survivors. Women with a history of estrogen-dependent cancers, clotting disorders, or cardiac risk. Millions of women, globally, with no real option. And for fifty years, the category waited.
The pharmaceutical industry kept iterating on estrogen. Different doses, different delivery methods, different combinations with progestin. The molecule stayed the same. The risk profile stayed the same.
JL-112 is that thing.
JASTLabs has developed a transdermal cream that treats vaginal atrophy and diminished libido using stabilized oxytocin and sildenafil. Applied topically in tiny amounts, it restores natural lubrication and physiological response. Designed for the women estrogen has failed and the women estrogen has excluded.
A new mechanism. A new category. The first real alternative in fifty years.
JL-112 is a proprietary transdermal cream that addresses the root physiology of menopausal vaginal atrophy and diminished libido. Applied in tiny amounts once daily, it acts locally to restore natural lubrication, vascular response, and tissue health.
JL-112 leverages a patent-pending stabilization platform that delivers therapeutic agents transdermally with peptide-grade efficiency. The mechanism is proprietary to JASTLabs and protected internationally.
A white, odorless cream applied in tiny amounts once daily. Designed for local action, with a clean tolerability profile and no oral systemic exposure.
The first topical, non-estrogen treatment developed for both menopausal vaginal atrophy and diminished libido. Patent-pending under the Patent Cooperation Treaty with 25+ international claims.
One standard of care. One open lane.
When Sildenafil launched in 1998, it did not just enter a category. It created one. A multi-billion-dollar market existed within five years for a patient population pharma had previously walked past.
JL-112 is the same kind of move on the other side of the room. A novel, patent-pending treatment built specifically for the menopausal patient, the largest underserved population in pharmaceutical history.
Past category performance is not indicative of future results. This comparison is offered for educational framing only.
Lipitor became the highest-grossing pharmaceutical product in history by reaching a patient base the previous generation of treatments left underserved. The science was understood. The category was open. Execution turned it into a global standard of care.
The JASTLabs thesis applies the same kind of logic to a non-hormonal women's health treatment. A novel, patent-pending formulation. A category pharma overlooked. A regulatory pathway designed to move faster than a traditional discovery program.
Past category performance is not indicative of future results. JL-112 has not received FDA approval and there is no guarantee it will.
Capital deployed into formulation and stability work.
Dual-direction stable formulation achieved.
Formulation tested and validated for the intended regimen.
PCT/CA2025/050571 filed April 22, 2025. Global IP fortification underway.
Up to $750K. Bridge to Reg A+ qualification.
Regulatory packaging, documentation, and pre-NDA work underway.
Q2 2026. The next regulatory step in the path to approval.
JASTLabs operates a streamlined commercial model. JL-112 reaches patients through the prescribing channels they already use, with no need for a custom sales force or distribution build-out.
Patients with persistent symptoms that affect comfort and daily function actively seek better options.
Distributed through standard pharmacy and telehealth, no new infrastructure required.
Each patient receives JL-112 on prescription from their physician, gynecologist, or endocrinologist.
JL-112 follows an eight-month regimen of one bottle per month. Re-treatment patterns generate recurring revenue per patient.
~$5,200 per patient, per year. Recurring revenue, prescription-driven, on existing channels.
The vaginal atrophy treatment market is projected to grow from $2.8B in 2023 to approximately $5.0B in 2030. The female sexual dysfunction market is projected to grow from $1.0B in 2023 to approximately $4.0B in 2032.
Market figures referenced in JASTLabs Pitch Deck v.25.12.20.2025 and supporting research.
| Year | Base Case | Pessimistic | Optimistic |
|---|---|---|---|
| 2030 | $32M | $32M | $32M |
| 2031 | $225M | $135M | $315M |
| 2032 | $420M | $295M | $600M |
| 2033 | $675M | $448M | $950M |
| 2034 | $1,125M | $750M | $1,500M |
| 2035 | $1,650M | $1,238M | $2,063M |
3% US share at launch (2030), scaling to 20% global category share by 2035.
Second indication (libido in menopausal women) approved and launched.
Projections are forward-looking and reflect management estimates. They are not guarantees. Actual results may differ materially.
Dr. Peddle, a practicing Canadian physician, reached for a similar oxytocin and sildenafil combination well before JASTLabs existed, prepared one prescription at a time through compounding pharmacies for his own patients.
JASTLabs took that hands-on precedent and engineered it into JL-112: a single, stabilized formulation built for consistency, scale, and a defined regulatory path. The science behind the product reflects a combination physicians have already worked with by hand.
References to compounded preparations describe individual physician practice. They do not constitute a claim regarding JL-112, which has not received FDA approval.
Former Pfizer executive. Executive MBA from INSEAD. Thirty-plus years building life science brands across pharma, marketing, sales, and business development. Early leader in the Canadian medical cannabis category. Primary point of contact for investor calls.
Forty-five years practicing Ontario law. Specializes in commercial real estate, joint ventures, and institutional legal expertise. Trusted intermediary for Canada's major banks. Active investor in multiple ventures.
Career operator across pharmaceutical manufacturing and regulatory work. Past roles at Orbus Pharma, Sanitas Pharmaceuticals, CMAX Technologies, and Canntab Therapeutics.
Multi-decade pharma career covering foundational science through corporate management. International track record converting pharma ideas into market-accepted outcomes.
Master's in Pharmacy. Quality control and quality assurance expertise. Owns regulatory compliance for JL-112.
Thirty-plus years in cross-border business and intellectual property. Former US patent prosecutor for 25 years. Past roles at Wyeth Pharmaceuticals, Genetics Institute, and General Counsel at Iovate.
We are not guessing at what works. We are applying decades of pharmaceutical experience to a smarter, faster, more capital-efficient model.
Michael Rubin Chief Executive Officer · JASTLabs Corporation
Future pricing reflects management's planned next round and is not guaranteed. Subsequent rounds are subject to capital, regulatory, and market conditions.
| Investment | Price / Share | Volume Discount |
|---|---|---|
| $10,000 - $24,999 | $2.00 | Standard |
| $25,000 - $49,999 | $1.90 | 5% off |
| $50,000 - $99,999 | $1.80 | 10% off |
| $100,000 - $249,999 | $1.70 | 15% off |
| $250,000 - $499,999 | $1.60 | 20% off |
| $500,000 - $1,999,999 | $1.50 | 25% off |
| $2,000,000 + | $1.40 | 30% off (max) |
Volume pricing applies to the current Reg D 506(c) round for accredited investors. Final share price is confirmed at subscription. Figures are illustrative and subject to the offering documents.
Formulation development, lab testing, clinical design and Phase 1 and 2 trials, patent fortification, Reg A+ public process, SOP and software, FDA fees, and regulatory contracting.
Salaries, lab leasing, outsourced regulatory contracts, accounting, auditing, public legal, day-to-day operations. Includes $1M retention fund.
This is a private investment in an early-stage pharmaceutical company. Loss of all capital is possible. Specific risks include but are not limited to the following.
FDA review timelines and outcomes are uncertain. A faster regulatory path reduces capital and time exposure. It does not guarantee approval.
JL-112 has not yet undergone the controlled clinical trials required for FDA approval. Clinical outcomes are uncertain until those trials are completed, and approval is not guaranteed.
Forecasted market share assumptions are estimates. Actual uptake depends on prescriber adoption, payer dynamics, and competitive response.
Shares purchased in this round are private and not freely tradable. Exit timing depends on future financing, licensing, acquisition, or IPO events.
Forward-looking projections reflect management estimates. Actual financial results may differ materially.
Investors should review the full offering documents and consult their own financial and legal advisors before participating.
For accredited investors who want the complete picture before subscribing. Submit your details and we will send the investor brief, schedule a call if requested, and walk you through the offering documents.
The current Reg D 506(c) round is open to accredited investors. Review the offering, request the full investor brief, or speak directly with Michael Rubin and Eric Lehner before you decide.
Investor Relations: Eric Lehner • [email protected]
THE SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES OR BLUE SKY LAWS AND ARE BEING OFFERED AND SOLD IN RELIANCE ON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND STATE SECURITIES OR BLUE SKY LAWS. ACCORDINGLY, THE SECURITIES CANNOT BE SOLD OR OTHERWISE TRANSFERRED EXCEPT IN COMPLIANCE WITH THE ACT. IN ADDITION, THE SECURITIES CANNOT BE SOLD OR OTHERWISE TRANSFERRED EXCEPT IN COMPLIANCE WITH THE APPLICABLE STATE SECURITIES OR BLUE SKY LAWS. THE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SEC, ANY STATE SECURITIES COMMISSION OR OTHER REGULATORY AUTHORITY, NOR HAVE ANY OF THE FOREGOING AUTHORITIES PASSED UPON THE MERITS OF THIS OFFERING OR THE ADEQUACY OR ACCURACY OF ANY OTHER MATERIALS OR INFORMATION MADE AVAILABLE TO SUBSCRIBER IN CONNECTION WITH THIS OFFERING. ANY REPRESENTATION TO THE CONTRARY IS UNLAWFUL.
THE SECURITIES MAY ONLY BE PURCHASED BY PERSONS WHO ARE “ACCREDITED INVESTORS” (AS THAT TERM IS DEFINED IN SECTION 501 OF REGULATION D PROMULGATED UNDER THE ACT).
THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS
Manhattan Street Capital is compensated by Jastlabs Corporation for project management $10,000 per month listing the offering of the issuer’s securities $5,000 per month (charged as one payment for multiple offerings), and technology administration ($400 per investment by individuals, $1000 per investment for IRAs, Trusts or by US companies, LLCs or LPs, and $5000 per investment for professional investment entities. Payment is made in cash and a matching warrant. MSC might earn up to an estimated maximum amount of $3,000,000 on this offering.
Comments
Post comment